ClinicalTrials.gg
CompletedNCT03483545MARCSUpdated Aug 28, 2019

Menopur And Rekovelle Combination Study

An interventional study of Follitropin delta and HP-hMG in Fertility Disorders, sponsored by Dr François Bissonnette. Completed at 4 sites in Canada. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Dr François Bissonnette · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study proposes to evaluate the effect of adding HP-hMG (Menopur) to follitropin delta in a "mixed protocol" regimen, using an individualized, fixed dose of follitropin delta based on the established algorithm, combined with a variable, adjustable dose of Menopur based on body weight and ovarian reserve.

Read the detailed description

The initial dose of follitropin delta will be determined at enrolment by the analysis of serum AMH on days 2 to 5 of the menstrual cycle preceding the IVF treatment cycle and body weight in Kg The initial dose of HP-hMG to be added on top of follitropin delta will be determined at enrolment by the total follitropin delta dose and body weight in Kg

02

Conditions studied

  • Fertility Disorders

Keywords

  • Ovarian Response
  • In vitro fertilization
  • Controlled ovarian stimulation
03

In context

Lead sponsor

This is the only study on the registry with Dr François Bissonnette as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 18 to 40 years of age undergoing their first IVF/ICSI cycle
  • Diagnosed with unexplained infertility, tubal infertility, endometriosis stage I/II, or with partners diagnosed with male factor infertility
  • Regular menstrual cycles of 24-35 days
  • Presence of both ovaries
  • Early follicular phase FSH serum concentration \<10 IU/L measured between Day 2 to Day 5 of menstrual cycle within the previous 12 months
  • Ejaculated sperm (fresh or frozen) for insemination

Exclusion criteria

Exclusion Criteria:

  • Inability to consent
  • Endometriosis stage III and IV
  • High risk of OHSS (AMH ≥ 35 pmol/L)
  • History of recurrent miscarriages defined as ≥ 3 consecutive losses
  • Women undergoing egg donation
  • Women participating in any other research project
  • Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle
  • to follitropin delta and/or HP-hMG
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Follitropin delta and HP-hMG

    Follitropin delta combined with highly purified human menopausal gonadotrophin

    Combination Product: Follitropin delta and HP-hMG

Interventions

  • Combination productFollitropin delta and HP-hMG

    Drug page: Follitropin delta

    Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg

06

What researchers measure

Primary outcomes

  1. Evaluate the number of utilizable blastocysts on Day 5 or Day 6 of embryo culture

    Utilizable blastocyst is defined as embryo at day 5 or 6 suitable for transfer

    Time frame: 6 days of embryo culture

Secondary outcomes

  1. Determine dosage of REKOVELLE and Menopur in a mixed protocol

    Evaluate the effect of adding HP-hMG (Menopur) to follitropin delta (REKOVELLE) during IVF stimulation

    Time frame: up to 20 days

  2. Evaluate the safety profile of the REKOVELLE - Menopur mixed protocol algorithm

    The safety profile is the proportion of women with early and late OHSS and/or preventive interventions for early OHSS (i.e., triggering with GnRH agonist, use of dopamine agonist, conversion of planned fresh transfer into a freeze-all). OHSS is defined as an iatrogenic complication that occurs mainly due to ovarian overstimulation by gonadotropins.

    Time frame: up to 20 days

07

Study locations

4 sites
  • Olive Fertility Centre
    Vancouver, British Columbia V5Z 3X7, Canada
  • Hannam Fertility Centre
    Toronto, Ontario M4W 3R2, Canada
  • CReATe Fertility Centre
    Toronto, Ontario M5G 1N8, Canada
  • Clinique Ovo
    Montreal, Quebec H4P 2S4, Canada
08

References and documents

Publications

  • Bissonnette F, Minano Masip J, Kadoch IJ, Librach C, Sampalis J, Yuzpe A. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil Steril. 2021 Apr;115(4):991-1000. doi: 10.1016/j.fertnstert.2020.09.158. Epub 2020 Nov 30. PubMed 33267959 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jul 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 30, 2018
StartActual
Jul 17, 2018
Primary completionActual
Jul 31, 2019
CompletionActual
Jul 31, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03483545
Lead sponsor
Dr François Bissonnette
Collaborators
Create Fertility Center, Olive Fertility Centre, Hannam Fertility Centre
Responsible party
Dr François Bissonnette (Principal Investigator, Clinique Ovo) — Sponsor-investigator
First posted
Mar 30, 2018
Start date
Jul 17, 2018
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Last update
Aug 28, 2019

Study contacts

François Bissonnette, MD
principal investigator · Clinique Ovo
Clifford Librach, MD
principal investigator · CReATe Fertility Centre
Tom Hannam, MD
principal investigator · Hannam Fertility Centre
Al Yuzpe, MD
principal investigator · Olive Fertility Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion